DadFinStart your free week
DadFin › Stocks › Healthcare › DGX

Quest Diagnostics Incorporated (DGX) stock score

Healthcare · Diagnostics & Research · United States

$230.97 ▲ +0.07% today

94.0
Dad Score, out of 100
strong

Quest Diagnostics Incorporated (DGX) is a Diagnostics & Research company in the Healthcare sector, listed in the United States. On DadFin's weekly run it scores 94.0 out of 100 on the Dad Score, a strong reading that places the business ahead of 94% of the 5,774 US and Canadian stocks DadFin fully scores. Inside Healthcare it ranks #53 of 974. Its strongest axes are valuation, quality and growth; its weakest is conviction.

Scores from the run of Oct 4, 2026. The Dad Score answers one question: how good is this business, measured against its own sector. How it is built →

The eight axes

Valuation
Strong
Quality
Strong
Growth
Strong
Price action
Average
Risk
Strong
Conviction
Below average
Liquidity
Strong
Macro
Above average

Each axis is ranked inside the stock's own sector. Subscribers see the percentile and every input behind each bar.

Key numbers

P/E (trailing)24.7×
P/E (forward)19.4×
Dividend yield1.44%
Return on capital11.4%
Operating margin15.2%
Revenue growth (YoY)+11.8%
FCF yield4.3%
Net debt / EBITDA2.55×
Piotroski F-Score8 / 9
52-week change+32.5%
Market cap$25.8B
Next earningsOct 22, 2026

What subscribers see on DGX

Start your free weekSubscriber? Open the full research →

Diagnostics & Research peers

StockCompanyDad ScoreBandMarket cap
TMOThermo Fisher Scientific Inc.77.0good$242.1B
DHRDanaher Corporation79.6good$150.5B
NTRANatera, Inc.86.1strong$59.1B
AAgilent Technologies, Inc.79.9good$47.3B
IQVIQVIA Holdings Inc.82.3good$42.5B
WATWaters Corporation78.8good$41.7B
ILMNIllumina, Inc.35.1weak$41.2B
IDXXIDEXX Laboratories, Inc.90.1strong$40.9B

Prices from DadFin's live feed (refreshed about every 15 minutes in the session); scores from the weekly run of Oct 4, 2026. Fundamentals as reported in the latest filings. Research, not investment advice.